Program to understand and treat Hypertrophic Cardiomyopathy in Egypt

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The Egyptian Hypertrophic Cardiomyopathy Program aims to define the incidence, severity, phenotype, and genotype of Hypertrophic Cardiomyopathy (HCM) in Egypt. It involves characterizing large cohorts of patients with inherited muscle disease and their relatives, while also providing tailored treatment strategies that include medical, surgical, and interventional procedures. The program focuses on studying the basic mechanisms of the disease at a molecular level and aims to train local cardiologists and surgeons in advanced diagnostic and management techniques. Additionally, it seeks to explore the role of microvascular coronary arteries in disease progression.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* All patients diagnosed with hypertrophic cardiomyopathy (index patients) who are willing and consented to participate in the registry.
* All family members of index patients who are willing and consented to participate in the registry.

Exclusion Criteria:

* Refusal to consent to participate in the registry program.

Where it's running

• Aswan Heart Centre - Magdi Yacoub Heart Foundation
  Aswān, Egypt Recruiting

Study contacts

• Study coordinator: Magdi H Yacoub, FRS OM
• Email: m.yacoub@imperial.ac.uk

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Mavacamten for symptomatic obstructive hypertrophic cardiomyopathy in Chinese adults

  This project will test how well mavacamten works for Chinese adults with symptomatic obstructive hypertrophic cardiomyopathy when used in everyday clinical care.

  Recruiting at 10 sites Bristol-Myers Squibb · Beijing, Beijing Municipality and 14 other locations · NCT07361289

• Long-term safety of HRS-1893 for people with hypertrophic cardiomyopathy

  This study tests the long-term safety of the oral drug HRS-1893 in people with hypertrophic cardiomyopathy who previously received HRS-1893.

  Recruiting Phase 2 Shandong Suncadia Medicine Co., Ltd. · Beijing, Beijing Municipality · NCT07021963

• Study of heart conditions using advanced imaging techniques

  This study is trying to find out what causes different heart conditions in Hispanic and African American people in the Bronx by using advanced imaging techniques.

  Recruiting Montefiore Medical Center · The Bronx, New York · NCT06610019

• Registry for Rare Diseases

  This study is creating a detailed registry to collect information on rare diseases like amyloidosis and sarcoidosis to help improve how they are diagnosed and treated.

  Recruiting Hospital Italiano de Buenos Aires · Buenos Aires, Buenos Aires · NCT06573723

• Comparing inspiratory muscle training and Baduanjin exercises for heart health

  This study tests whether breathing exercises or a special exercise program can help people with hypertrophic cardiomyopathy improve their lung function, exercise ability, and overall quality of life.

  Recruiting Istanbul University - Cerrahpasa · Istanbul · NCT06490250

• Using advanced imaging to evaluate heart muscle scarring in various heart conditions

  This study is testing a new imaging method to see how heart scarring changes over time in people with certain heart conditions.

  Recruiting University of Edinburgh · Edinburgh, Scotland · NCT06409585

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.